Background: Increased level of hydrogen sulphide (H 2 S) in sputum is reported to be
| INTRODUCTION
Asthma is characterized by a chronic airway inflammatory process that leads to bronchial hyperresponsiveness and bronchodilator response to b-adrenergic agonists. 1 This inflammatory profile can be varied on the basis of the predominant inflammatory cell types involved: eosinophilic, neutrophilic and paucigranulocytic. 2, 3 It has been understood that these inflammatory phenotypes are strongly linked with distinct clinical features, such as response to treatment. The presence of eosinophilic inflammation may be indicative of good therapeutic response to corticosteroid therapy, while that of neutrophilic inflammation may be the most frequent indication of corticosteroid insensitivity. 4, 5 Asthma severity can also be categorized according to these inflammatory phenotypes. Moore et al indicated that subjects with mild-to-moderate allergic asthma were likely to have minimal or eosinophilic predominant sputum inflammation, whereas those who had moderate-to-severe asthma showed neutrophilic-predominant sputum inflammation either alone or with eosinophilic sputum inflammation. In addition, sputum neutrophil percentages were the second most influential variable for detecting severe asthma. 3 Therefore, if there were several biomarkers simply identifying these inflammatory phenotypes, it would be possible to accurately recognize the different clinicopathophysiological characteristics of asthma. In recent years, fractional exhaled nitric oxide (FeNO) [6] [7] [8] [9] and periostin 10, 11 have been recognized as biomarkers of eosinophilic predominant asthma and are suggested to be markers of therapeutic response to corticosteroids, as well as biologic agents such as omalizumab, mepolizumab and lebrikizumab. [12] [13] [14] [15] [16] On the other hand, there has yet to be a useful biomarker of non-eosinophilic predominant asthma that is concurrently associated with the pathophysiological features of asthma.
Hydrogen sulphide (H 2 S), a gas with a typical malodorous smell, is produced by many cell types in the lungs including pulmonary arterial cells, airway smooth muscle cells, lung primary fibroblasts and endothelial cells [17] [18] [19] [20] through the action of three H 2 S synthetics:
cystathionine-b-synthase (CBS), cystathionine-c-lyase (CSE) and 3-mercaptopyruvate sulfurtransferase (3-MST). 21 ,22 H 2 S is now considered to be the third gasotransmitter along with nitric oxide (NO) and carbon monoxide (CO). 20 There have been few clinical studies published on H 2 S in respiratory diseases. We previously reported that serum and sputum H 2 S levels in asthmatic subjects were higher compared to healthy subjects and positively correlated with sputum neutrophils, 23 indicating that H 2 S could be a marker of neutrophil dominant asthma. However, relationships between H 2 S and disease activities in asthma remain unclear.
The aims of this study were, firstly, to compare serum and sputum H 2 S levels in asthmatic subjects during different conditions defined as controlled, uncontrolled and in exacerbation state, and secondly, to evaluate whether H 2 S could be an independent biomarker of neutrophilic airway inflammation in asthma.
| METHODS

| Subjects
In total, 68 stable asthmatic subjects and 26 asthmatic subjects with acute exacerbation were recruited from a clinic belonging to Fukush- 
| Definition of asthma control and exacerbation
Asthmatic subjects were categorized as having controlled, partly controlled or uncontrolled asthma according to the Global Initiative for Asthma (GINA) guidelines. 1 Uncontrolled asthmatic subjects (UC-BA)
were defined as having three or more of following features over 4 weeks before recruitment: (1) daily symptoms more than twice a week; (2) 
| Study design
This was a cross-sectional observational study. At study entry, asthma control and exacerbation were assessed using the abovementioned methods. Spirometry, FeNO measurements and sputum and peripheral blood samplings for the measurements of H 2 S, as well as interleukin (IL)-8 and IL-5, were performed. An asthma control test (ACT) questionnaire was also administered to all asthmatic subjects. 25 After the enrolment, all asthmatic subjects were asked to keep a record of exacerbations over the course of a year and were reviewed every 3 months. In 13 asthmatics, H 2 S levels in sputum and serum were obtained during exacerbation and during stable state.
| Sputum induction and processing
Sputum induction was performed with inhaled nebulized 5.0% NaCl solution. 26 Sputum plugs were harvested and processed with 0.1% Finetech Japan Corporation, Tokyo, Japan) were prepared for differential cell counts.
| Blood processing
Next, 10 mL of blood was obtained and centrifuged at 800 g for 10 minutes. Then, 1 mL serum was aliquoted into the serum tube and 1 mL of SAOB II was added in the same way as the sputum processing and the mixture was stored at À80°C for later measurements of H 2 S. The rest of the serum samples were also stored as they were at À80°C for later analysis of cytokine and chemokine.
| Measurement of H 2 S
H 2 S levels in the serum and sputum were measured using a sulfidesensitive electrode (Model 9616; Orion Research; Beverly, MA, USA). Briefly, standard solutions were made using 0.1% DTT plus saline or saline only for sputum and serum H 2 S measurements, respectively, to minimize any effect of DTT. The electrode was placed into the standard solutions for measurement of H 2 S levels, and a calibration standard curve was constructed. The electrode was then put into the samples, and the H 2 S concentrations were calculated using the calibration standard curve. Validation of the H 2 S measurements, including accuracy, reproducibility and storage effects of samples, has been reported elsewhere. 
| Measurement of IL-5 and IL-8
IL-5 and IL-8 levels in serum and sputum supernatants were measured as one of the Th2 and Th1 type of inflammatory markers, respectively, using a commercially available sandwich ELISA kit (R&D Systems, Minneapolis, Minnesota, USA). Table 1 shows the clinical characteristics of the subjects. Age and FeNO levels were significantly higher, and height, sputum macrophages and FEV 1 /FVC were significantly lower in all asthmatic subjects than in the healthy subjects (P < .01). Sputum neutrophils in all asthmatic subjects were higher than in the healthy subjects, although those in the UC-BA subjects did not reach a level of significance.
| Statistical analysis
| RESULTS
| Characteristics of participants
Sputum eosinophils were significantly higher in the UC-BA subjects than in the healthy subjects (P < .05).
| H 2 S levels in serum and sputum
Sputum H 2 S levels in the AE-BA subjects (median 30.1 lmol/L; IQR 22.5-46.6 lmol/L) were significantly higher compared to the healthy subjects (median 13.0 lmol/L; IQR 9.9-15.6 lmol/L) (P = 
| Sputum-to-serum H 2 S ratio
We examined the ratio of H 2 S in sputum to that in serum (H 2 S ratio). This H 2 S ratio in the AE-BA group (median 0.40; IQR 0.39-0.76) was significantly higher than that in the healthy subjects (me- 
| Relationships between H 2 S levels and asthma parameters
Sputum H 2 S levels showed a negative correlation with sputum macrophages (%) (r = À.523, P = .001) and a positive correlation with sputum neutrophils (%) (r = .371, P = .014). There were no correlations between sputum H 2 S levels, FEV 1 /FVC, FeNO levels and ACT scores, although there was a non-significant trend between sputum H 2 S and FEV 1 %predicted (Table 2) .
Serum H 2 S levels did not correlate with any parameters related to asthma, such as inflammatory cell differentials in blood and sputum, FeNO levels, ACT scores and lung function ( Table 2 ).
According to the multiple linear regression analysis, sputum H 2 S was independently associated with increased sputum neutrophil percentage and decreased FEV 1 %predicted (P < .05) ( Table 3 ). There was no parameter independently associated with serum H 2 S levels.
Sputum and serum H 2 S levels were not influenced by age, sex, height or weight.
| IL-8 and IL-5 levels in serum and sputum
IL-8 and IL-5 levels only in serum, but not in sputum, were higher in the AE-BA subjects compared to the healthy subjects. We investigated whether the sputum-to-serum ratios of each IL-8 and IL-5 levels were also altered during exacerbations. There were no significant differences in the sputum-to-serum ratios of each IL-8 and IL-5 between the groups (Figure 4 ).
| Relationships between H 2 S levels and Th1 and
Th2 markers
Sputum H 2 S levels showed significant positive correlations with IL-8 levels in serum (r = .525, P = .001), as well as in sputum (r = .359, P = .031), but not with IL-5 levels in either serum or sputum. On the other hand, serum H 2 S levels correlated with IL-5 levels (r = .263, P = .029) and IL-8 levels (r = .232, P = .041) only in serum, but not in sputum (Table S1 ). 
| H 2 S ratio as onset of asthma exacerbations
A ROC curve was constructed to determine the cut-off level of H 2 S ratio that indicates an ongoing exacerbation from stable asthma. The optimal cut-off level of H 2 S ratio was ≥0.34 (area under the curve; 0.88, sensitivity of 81.8% and specificity of 72.7%, P < .001) (Figure 5 ).
| Predicting future risks of asthma exacerbation using H 2 S ratio
Thirty asthmatic subjects (11 S-BA, 10 UC-BA and nine AE-BA), who simultaneously yielded enough sputum and serum samples for the measurement of H 2 S could be followed over the course of a year.
Over the next 3 months after enrolment, six (46.2%) asthmatic subjects with a H 2 S ratio of 0.34 or more experienced at least one or more asthma exacerbations, while only one (5.9%) asthmatic subject with a H 2 S ratio of <0.34 suffered from an exacerbation (P = .01) (Table 4) . This difference was not observed over the next 6, 9 and 12 months. Furthermore, H 2 S ratio showed a significant negative correlation with the time interval from asthma exacerbation onset to a hospital visit, that is, the greater the H 2 S ratio was, the shorter the time of presentation to hospital (r = À.443, P = .014).
Additionally, there were no significant differences between the subjects who provided sputum and serum samples simultaneously and those who did not in terms of asthma control status and clinical characteristics, including lung function parameters, sputum cell differentials and H 2 S levels in sputum and serum.
| DISCUSSION
In patients with asthma, sputum H 2 S levels were significantly higher in the AE-BA subjects compared to the UC-BA and healthy subjects.
On the contrary, serum H 2 S levels were higher in the S-BA subjects than in the healthy subjects, and the UC-BA and AE-BA F I G U R E 1 H 2 S levels in sputum (A) and serum (B) from stable controlled asthmatic subjects (S-BA:■), uncontrolled asthmatic subjects (UC-BA:▲), asthmatic subjects with acute exacerbation (AE-BA:▼) and healthy subjects (Healthy:•). Horizontal bars indicate the median values F I G U R E 2 Difference in serum H 2 S levels between stable and exacerbation states in the same asthmatic subjects. During the exacerbation state, serum H 2 S levels mostly decreased from those in the stable state F I G U R E 3 Sputum-to-serum H 2 S ratio in stable controlled asthmatic subjects (S-BA:■), uncontrolled asthmatic subjects (UC-BA:▲), asthmatic subjects with acute exacerbation (AE-BA:▼) and healthy subjects (Healthy:•). Horizontal bars indicate median values subjects had similar serum H 2 S levels to the healthy subjects. Serum H 2 S levels significantly dropped during exacerbation in asthmatics that had H 2 S levels previously measured while their asthma was stable. Thus, the H 2 S ratio in the AE-BA subjects was higher than in the S-BA, UC-BA and healthy subjects. Furthermore, half of the asthmatic subjects with a H 2 S ratio higher than the cut-off level experienced at least one or more asthma exacerbations over the next 3 months after the study enrolment. Finally, sputum H 2 S levels showed a trend to decrease with FEV 1 %predicted and positive correlations with sputum neutrophils (%), sputum IL-8 and serum IL-8 levels, indicating that sputum H 2 S levels may be associated with obstructive neutrophilic-predominant airway inflammation in asthma.
This is the first study to examine the levels of H 2 S in serum and sputum during different conditions such as controlled, uncontrolled and acute exacerbation status in asthma. Our previous study reported that serum and sputum H 2 S levels in asthmatic subjects were higher compared to healthy subjects, although there was no significant difference between asthma severities. 23 These results were in concordance with those of the current study to a larger extent, but our new finding is that H 2 S levels in serum were lower in the UC-BA and AE-BA subjects than in the S-BA subjects. In addition, more interestingly, sputum H 2 S levels were higher in AE-BA subjects than in the S-BA and UC-BA, which were entirely opposite to serum H 2 S levels. These observations were further verified by the changes in serum H 2 S levels between the stable and the exacerbation state obtained from the same asthmatic subjects. There have only been two reports discussing the relationship between H 2 S levels and disease activity, although those investigations were all conducted in chronic obstructive pulmonary disease (COPD) subjects and not in asthmatic subjects. 27, 28 Chen et al 28 found that serum H 2 S levels in stable COPD patients were higher than in healthy nonsmokers and were lower than in COPD subjects with acute exacerbation. In addition, they also revealed that serum H 2 S levels were decreased among stable COPD patients depending on the stage of airway obstruction. 28 Similarly, we previously revealed that sputum H 2 S levels in COPD subjects with acute exacerbation were higher than in stable COPD and healthy subjects, but serum H 2 S levels in COPD subjects with acute exacerbation were lower than in stable COPD subjects. 27 These findings are quite comparable to our results and support our investigation suggesting that looking at changes in sputum and serum H 2 S levels could be used as a marker of identifying disease states, as well as ongoing exacerbation in asthma.
Furthermore, taking the results mentioned above into consideration, the H 2 S ratio may be expected to be more useful as a unique biomarker of a warning system for predicting the risk of exacerbations in asthma. This is because the systemic (serum) and the airway (sputum) levels of H 2 S showed an opposite alteration during an exacerbation. In fact, the H 2 S ratio increased to double the amount during acute exacerbation, and a ratio of ≥0.34 was indicative of an ongoing exacerbation. Moreover, half of the asthmatic subjects with a H 2 S ratio≥0.34 experienced asthma exacerbations in 3 months period. In contrast, sputum-to-serum IL-8 and IL-5 ratios did not differentiate the AE-BA subjects from the healthy or S-BA subjects. This difference between H 2 S ratio, IL-8 and IL-5 ratio for detecting asthma exacerbation can be explained by the finding that serum IL-8
and IL-5 levels increased in contrast to the reduction in serum H 2 S levels during exacerbations. Similar results have been reported in COPD patients, which revealed that H 2 S ratio increased during acute exacerbation in COPD patients. 27 These findings, taken together with our results, may suggest that H 2 S ratio, rather than single measurements of H 2 S levels either in serum or sputum, could be a more sensitive marker for not only reflecting ongoing exacerbation but also predicting future risks of asthma exacerbations.
The source of H 2 S in sputum and in serum in asthmatic subjects is currently being investigated. In blood circulation, it is likely that vascular endothelial cells and vascular smooth muscle cells produce H 2 S, 29 while in the airway, airway smooth muscle cells are likely to be the major source. 18, 20 In mouse lung, both H 2 S producing enzymes, CSE and CBS, are mainly expressed in pulmonary vascular smooth muscle cells and endothelial cells, as well as in airway smooth muscle cells. 20 Furthermore, increased expression of CBS was observed in airway smooth muscle cells from COPD patients. 18 These findings may underlie the increased H 2 S in sputum and serum, which is in agreement with previous studies. 23, 27, 28 However, the mechanisms by which H 2 S levels are decreased in serum and 30 and also suppress airway smooth muscle proliferation and IL-8 release. 18 In support of this effect, aggravated airway hyperresponsiveness and increased airway inflammation occurred in mouse models of asthma with deficiency of H 2 S-producing enzymes. 31 Therefore, H 2 S may have a protective role in asthma.
However, other studies have suggested that H 2 S has a proinflammatory role in controlling LPS-induced sepsis, 32 acute pancreatitis 33 and burn injury 34 and that inhibiting H 2 S was protective of organ injury in endotoxaemia. 32 Thus, systemic production of H 2 S might be down-regulated during an acute exacerbation, resulting in the decrease in serum H 2 S levels. Further investigations will be needed to investigate the interrelationships between systemic and airway production of H 2 S.
F I G U R E 4 IL-8 and IL-5 in sputum and serum, and their sputum-to-serum ratio in stable controlled asthmatic subjects (S-BA:■), uncontrolled asthmatic subjects (UC-BA:▲), asthmatic subjects with acute exacerbation (AE-BA:▼) and healthy subjects (Healthy:•). Horizontal bars indicate median values
The receiver operator characteristics curve for the sputum-to-serum H 2 S ratio to predict acute exacerbation of asthma It is important to detect neutrophilic airway inflammation in asthma because the presence of neutrophilic-predominant airway inflammation may be associated with more severe asthma and possibly, corticosteroid insensitivity. 4, 5 At present, a more convenient biomarker for neutrophilic asthma does not exist. In the present study, there was a positive correlation between sputum H 2 S levels and sputum neutrophils (%), which is in agreement with previous reports. 23, 27 The mechanism of the relationship between H 2 S and neutrophils in sputum is unclear. However, Dal-Secco et al 35 previously reported that the incubation of neutrophils with IL-8 enhanced H 2 S production in vitro study. We also found that sputum H 2 S levels showed positive correlations with IL-8 levels in sputum, as well as in serum. These findings, including our results, indicate that sputum H 2 S could be expected as a new non-Th2 biomarker for detecting neutrophilic airway inflammation.
In our study, a relationship was observed between sputum H 2 S and the degree of airflow obstruction obtained from the multiple linear regression analysis although this relationship was weak. A similar result was observed in our previous cohort in asthma and COPD where the higher levels of sputum H 2 S, the higher the degree of airflow obstruction 23, 27 . This indicates that H 2 S can be considered as a biomarker not only of airway inflammation but also of airflow obstruction. Supporting the above-mentioned relationship, only FEV 1 %predicted and sputum neutrophilia were independently associated with sputum H 2 S when using a multiple linear regression analysis. Therefore, sputum H 2 S could be a surrogate biomarker for detecting obstructive neutrophilic airway inflammation in asthma.
There are several limitations in this study. Firstly, sputum and serum samples were obtained simultaneously from only 30 asthmatic subjects because many asthmatic subjects were not able to produce adequate amount of sputum for measuring H 2 S levels. However, we believe the influence of this selection bias on H 2 S levels would be small because a proportion of the subjects included for the ROC analysis were balanced in regard to asthma status. In addition, there were no significant differences in subjects' characteristics between those who provided sputum and serum samples concurrently and those who did not. Secondly, serum H 2 S levels may be influenced by systemic non-respiratory diseases such as heart, hepatic, renal and pancreatic disease. 36 However, there was no significant difference in serum H 2 S levels between the absence and presence of these diseases (data not shown). Thirdly, the effect of asthma medication on H 2 S is not known. However, there was no significant difference in serum and sputum H 2 S levels between subjects with or without inhaled corticosteroid in this study (data not shown). In addition, a previous study revealed that inhaled corticosteroids and theophylline had no effect on H 2 S levels in COPD patients. 37 Therefore, we believe that the influence of asthma medication on H 2 S was negligible. Finally, bacteria in the upper and lower airways may contribute to H 2 S production. 27 H 2 S produced by bacteria may sustain bacterial growth and suppress its sensitivity to antibiotics. 38 Thus, H 2 S could partly reflect the presence of bacterial infection in the airways and lungs.
In conclusion, concomitant measurements of H 2 S in sputum and serum may provide useful information for evaluating asthma conditions, especially predicting future risks of asthma exacerbations. Furthermore, sputum H 2 S levels, rather than serum H 2 S levels, may represent a novel promising biomarker of neutrophilic-predominant airway inflammation in asthma. In the future, further prospective studies will be required to investigate whether H 2 S ratio could estimate the therapeutic response to poorly controlled asthma in a large asthma cohort.
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